<DOC>
	<DOCNO>NCT01623570</DOCNO>
	<brief_summary>The aim study compare efficacy safety r-hFSH+r-hLH 2:1 ratio human Menopausal Gonadotropin Highly Purified ( hMG-HP ) , WHO type I anovulation , HH woman . This open-label monocentric , randomize comparative trial , receive two different standard clinical practice treatment : - 1 vial Pergoveris : ( vial/powder 150 International unit ( IU ) r-hFSH+ 75IU r-hLH ) - 2 vial Menopur : ( vials/powder hMG 75IU ) . Follicular development monitor protocol hCG requirement meet single injection hCG administer . Main Outcome Measures follicular development i.e . follicle ≥ 17 millimeter ( mm ) , pre-ovulatory E2 ≥ 400 picomole/Liter ( pmol/L ) mid-luteal phase Progesterone ( P4 ) ≥ 25 nanomole/Liter ( nmol/L ) .</brief_summary>
	<brief_title>Clinical Outcomes WHO Type I Anovulatory Women Using r-hFSH+r-hLH 2:1 Ratio hMG-HP</brief_title>
	<detailed_description>World Health Organization ( WHO ) type I hypogonadotropic anovulation ( hypogonadotropic hypogonadism , HH ) rare alteration reproductive system absent decrease function gonad , cause congenital , include genetic , acquire reduce hypothalamic pituitary activity . This result abnormally low serum level Follicular Stimulation Hormone ( FSH ) Luteinizing Hormone ( LH ) negligible oestrogen ( E2 ) activity . The convenient treatment daily injection exogenous gonadotropin proven effective . Patients lack effective hypothalamic-pituitary activity ( WHO type I anovulation ) produce sufficient threshold level endogenous LH , require obtain optimal follicular development steroidogenesis treat FSH alone . Therefore combination therapy adequate dos FSH LH optimal ratio require order restore fertility . The LH activity could produce LH human Chorionic Gonadotropin ( hCG ) two gonadotropin available use WHO type I patient two different formulation indication type patient . It would worth interest ass two different formulation could elicit clinical outcome standard clinical practice . The aim study compare efficacy safety recombinant human FSH recombinant human LH ( r-hFSH+r-hLH ) 2:1 ratio human Menopausal Gonadotropin Highly Purified ( hMG-HP ) , contain LH-like activity , woman severe LH FSH deficiency ( WHO type I anovulation , HH ) . All patient diagnose HH accord negative progesterone ( P4 ) challenge test , serum LH &lt; 1.2 IU/L FSH &lt; 5 IU/L , transvaginal ultrasound show uterus midline echo , ovarian tumor cyst ≤ 13 small follicle ( mean diameter ≤ 10millimeters ( mm ) ) large section ovary , Body Mass Index ( BMI ) 18 32 Kilograms square meter ( Kg/m2 ) , systemic disease . In open-label monocentric , randomize comparative trial , patient randomize two arm 1:1 ratio , receive two different standard clinical practice treatment : - 1 vial Pergoveris : ( vial/powder 150 International Units ( IU ) r-hFSH+ 75IU r-hLH ) stimulation day 1 require hCG level meet . The dose adjusted stimulation Day 6 accord subject ovarian response standard clinical practice - 2 vial Menopur : ( vial/powder hMG contain 75IU FSH + 75IU LH-like activity ) . stimulation day 1 require hCG level meet . The dose adjusted stimulation Day 6 accord subject ovarian response standard clinical practice Follicular development monitor accord clinical practice ultrasound ( US ) and/or estradiol ( E2 ) level , protocol hCG requirement meet ( i.e. , least one follicle great equal 17 mm ) . After , single injection hCG administer order induce final oocyte maturation . Main Outcome Measures ovulation induction measure follicular development i.e . follicle ≥ 17 mm , pre-ovulatory E2 ≥ 400 picomole/Liter ( pmol/L ) mid-luteal phase Progesterone ≥ 25 nanomole/Liter ( nmol/L ) . Secondary efficacy endpoint include estradiol levels/follicle mid-cycle , number follicle mid-cycle pregnancy rate ( PR ) . Drug safety assess monitoring adverse event incidence local reaction drug injection local site . Ovarian hyperstimulation syndrome ( OHSS ) assess record accord Golan classification According protocol , patient initially treat one cycle . If consenting , patient become pregnant first cycle treat optional one two series cycle criterion randomization , i.e . maintain treatment previous cycle .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>WHO Type I HH Women Serum LH &lt; 1.2 IU/L Serum FSH &lt; 5 IU/L Age 2536 year No ovarian tumor No cyst ≤ 13 small follicle ( mean diameter ≤ 10mm ) BMI 18 32 Kg/m2 systemic disease</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Luteinizing Hormone</keyword>
	<keyword>Hypogonadotropic Hypogonadism</keyword>
	<keyword>Ovulation Induction</keyword>
	<keyword>Chorionic Gonadotropin</keyword>
</DOC>